Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 37, 2010, Pages 16280-16285

  Järås, Marcus ^a   Johnels, Petra ^a   Hansen, Nils ^a   Ågerstam, Helena ^a   Tsapogas, Panagiotis ^a   Rissler, Marianne ^a   Lassen, Carin ^a   Olofsson, Tor ^b   Bjerrum, Ole Weis ^c   Richter, Johan ^b   Fioretos, Thoas ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Antibody dependent cell mediated cytotoxicity; Biomarker; Cancer; Therapeutic antibody

Indexed keywords

BCR ABL PROTEIN; CD34 ANTIGEN; CD38 ANTIGEN; CYTOKINE ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN ANTIBODY; RETROVIRUS VECTOR; UNCLASSIFIED DRUG; ANTIBODY; CD38 PROTEIN, HUMAN; IL1RAP PROTEIN, HUMAN; MEMBRANE PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER STEM CELL; CELL ISOLATION; CELL KILLING; CELL POPULATION; CELL SELECTION; CELL SEPARATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; PHILADELPHIA CHROMOSOME NEGATIVE CELL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; RECEPTOR UPREGULATION; UMBILICAL CORD BLOOD; APOPTOSIS; CYTOLOGY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; METABOLISM; PATHOLOGY;

ANTIBODIES; ANTIGENS, CD34; ANTIGENS, CD38; APOPTOSIS; CELL SEPARATION; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MEMBRANE GLYCOPROTEINS; NEOPLASTIC STEM CELLS;

EID: 77958004008     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1004408107     Document Type: Article

References (40)

1. Nowel P, Hungerford D (1960) A minute chromosome in human chronic granulocytic leukemia. Science 132:1497.
2. Rowley JD (1973) Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 243:290-293.
3. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G (1985) Structural organization of the bcr gene and its role in the Ph' translocation. Nature 315:758-761. (Pubitemid 15022931)
4. Deininger MW, Goldman JM, Melo JV (2000) The molecular biology of chronic myeloid leukemia. Blood 96:3343-3356.
5. Fialkow PJ, Denman AM, Jacobson RJ, Lowenthal MN (1978) Chronic myelocytic leukemia. Origin of some lymphocytes from leukemic stem cells. J Clin Invest 62:815-823.
6. Kavalerchik E, Goff D, Jamieson CH (2008) Chronic myeloid leukemia stem cells. J Clin Oncol 26:2911-2915.
7. Jiang X, et al. (2007) Chronic myeloid leukemia stem cells possess multiple unique features of resistance to BCR-ABL targeted therapies. Leukemia 21:926-935.
8. Copland M, et al. (2006) Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction. Blood 107:4532-4539.
9. Jin L, Hope KJ, Zhai Q, Smadja-Joffe F, Dick JE (2006) Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat Med 12:1167-1174. (Pubitemid 44527352)
10. Tavor S, et al. (2004) CXCR4 regulates migration and development of human acute myelogenous leukemia stem cells in transplanted NOD/SCID mice. Cancer Res 64:2817-2824. (Pubitemid 38500620)
11. Jin L, et al. (2009) Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell 5:31-42.
12. Majeti R, et al. (2009) CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 138:286-299.
13. Eisterer W, et al. (2005) Different subsets of primary chronic myeloid leukemia stem cells engraft immunodeficient mice and produce a model of the human disease. Leukemia 19:435-441.
14. Bhatia M, Wang JC, Kapp U, Bonnet D, Dick JE (1997) Purification of primitive human hematopoietic cells capable of repopulating immune-deficient mice. Proc Natl Acad Sci USA 94:5320-5325.
15. Jiang X, et al. (2008) Stem cell biomarkers in chronic myeloid leukemia. Dis Markers 24:201-216. (Pubitemid 352039919)
16. Bruns I, et al. (2009) The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 23:892-899.
17. Diaz-Blanco E, et al. (2007) Molecular signature of CD34(+) hematopoietic stem and progenitor cells of patients with CML in chronic phase. Leukemia 21:494-504.
18. Estrov Z, et al. (1991) Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble IL-1 receptors: A novel application for inhibitors of IL-1 activity. Blood 78:1476-1484.
19. Hystad ME, et al. (2007) Characterization of early stages of human B cell development by gene expression profiling. J Immunol 179:3662-3671.
20. Castor A, et al. (2005) Distinct patterns of hematopoietic stem cell involvement in acute lymphoblastic leukemia. Nat Med 11:630-637. (Pubitemid 40868303)
21. Ema H, et al. (2006) Adult mouse hematopoietic stem cells: Purification and single-cell assays. Nat Protoc 1:2979-2987.
22. Jiang X, Lopez A, Holyoake T, Eaves A, Eaves C (1999) Autocrine production and action of IL-3 and granulocyte colony-stimulating factor in chronic myeloid leukemia. Proc Natl Acad Sci USA 96:12804-12809.
23. Petzer AL, et al. (1996) Characterization of primitive subpopulations of normal and leukemic cells present in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 88:2162-2171.
24. Morris JC, Waldmann TA (2009) Antibody-based therapy of leukaemia. Expert Rev Mol Med 11:e29.
25. Peters CJ, Theofilopoulos AN (1977) Antibody-dependent cellular cytotoxicity against murine leukemia viral antigens: Studies with human lymphoblastoid cell lines and human peripheral lymphocytes as effector cells comparing rabbit, goat, and mouse antisera. J Immunol 119:1089-1096.
26. Jørgensen HG, Allan EK, Jordanides NE, Mountford JC, Holyoake TL (2007) Nilotinib exerts equipotent antiproliferative effects to imatinib and does not induce apoptosis in CD34+ CML cells. Blood 109:4016-4019.
27. Graham SM, et al. (2002) Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 99:319-325.
28. Jiang X, et al. (2010) Properties of CD34+ CML stem/progenitor cells that correlate with different clinical responses to imatinib mesylate. Blood, doi 10.1182/blood-2009-05-222471.
29. Engler JR, et al. (2010) Chronic myeloid leukemia CD34+ cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 24:765-770.
30. Subramaniam S, Stansberg C, Cunningham C (2004) The interleukin 1 receptor family. Dev Comp Immunol 28:415-428.
31. Ali S, et al. (2007) IL-1 receptor accessory protein is essential for IL-33-induced activation of T lymphocytes and mast cells. Proc Natl Acad Sci USA 104:18660-18665. (Pubitemid 350210753)
32. Ren R (2005) Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 5:172-183.
33. Chalandon Y, et al. (2005) BCR-ABL-transduced human cord blood cells produce abnormal populations in immunodeficient mice. Leukemia 19:442-448.
34. Dick JE (2008) Stem cell concepts renew cancer research. Blood 112:4793-4807.
35. Nilsson M, Karlsson S, Fan X (2004) Functionally distinct subpopulations of cord blood CD34+ cells are transduced by adenoviral vectors with serotype 5 or 35 tropism. Mol Ther 9:377-388. (Pubitemid 38404526)
36. Järås M, et al. (2009) Expression of P190 and P210 BCR/ABL1 in normal human CD34(+) cells induces similar gene expression profiles and results in a STAT5-dependent expansion of the erythroid lineage. Exp Hematol 37:367-375.
37. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25:402-408. (Pubitemid 34164012)
38. Barbouti A, et al. (2003) Clinical and genetic studies of ETV6/ABL1-positive chronic myeloid leukaemia in blast crisis treated with imatinibmesylate. Br J Haematol 122:85-93.
39. Hogge DE, Lansdorp PM, Reid D, Gerhard B, Eaves CJ (1996) Enhanced detection, maintenance, and differentiation of primitive human hematopoietic cells in cultures containing murine fibroblasts engineered to produce human steel factor, interleukin-3, and granulocyte colony-stimulating factor. Blood 88:3765-3773.
40. Wilkinson RW, Lee-MacAry AE, Davies D, Snary D, Ross EL (2001) Antibody-dependent cell-mediated cytotoxicity: A flow cytometry-based assay using fluorophores. J Immunol Methods 258:183-191. (Pubitemid 33016538)